Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. Drug resistance is the major cause for therapeutic failure in PDAC patients with progressive disease. The mechanisms underlying resistance formation are complex and remain poorly understood.
To gain insights into molecular changes during the formation of resistance to oncogenic MAPK pathway inhibition we utilized short-term passaged primary tumor cells from ten PDACs of genetically engineered mice. We followed gain and loss of resistance upon MEKi exposure and withdrawal by longitudinal integrative analysis of whole genome sequencing, whole genome bisulfite sequencing, RNA-sequencing and mass spectrometry data.
We found that resistant cell populations under increasing MEKi treatment evolved by the expansion of a single clone but were not a direct consequence of known resistance-conferring mutations. Rather, resistant cells showed adaptive DNA hypermethylation of 209 and hypomethylation of 8 genomic sites, most of which overlap with regulatory elements known to be active in murine PDAC cells. Both DNA methylation changes and MEKi resistance were transient and reversible upon drug withdrawal. The effector caspase CASP3 is one of the 114 genes for which transcriptional downregulation inversely correlated with the methylation status of the associated DNA region. CASP3 inactivation in resistant cells led to attenuation of drug-induced apoptosis which could be reversed by DNA methyltransferase inhibition with remarkable sensitivity exclusively in the resistant cells.
Overall, our data provide a context for characterization and targeting of epigenetically mediated resistance mechanisms in PDAC.
Competing Interest Statement
Jens Siveke reports institutional research funding from BMS, Celgene and Roche; compensated consulting from AstraZeneca, Bayer, Immunocore, Roche, Servier. He holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work. No disclosures were reported by the other authors.
Footnotes
Disclosure of Potential Conflicts of Interest Jens Siveke reports institutional research funding from BMS, Celgene and Roche; compensated consulting from AstraZeneca, Bayer, Immunocore, Roche, Servier. He holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work. No disclosures were reported by the other authors.
